Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

[1]  E. Antonarakis,et al.  BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Higano,et al.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Trock,et al.  Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer , 2020, Clinical Cancer Research.

[4]  W. Foulkes,et al.  Etiologic Index - A Case-Only Measure of BRCA1/2-Associated Cancer Risk. , 2020, The New England journal of medicine.

[5]  E. Antonarakis,et al.  PARP inhibitors in prostate cancer: time to narrow patient selection? , 2020, Expert review of anticancer therapy.

[6]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[7]  E. Antonarakis,et al.  Therapeutic targeting of the DNA damage response in prostate cancer. , 2020, Current opinion in oncology.

[8]  F. Feng,et al.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.

[9]  F. Saad,et al.  TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). , 2020 .

[10]  Z. Szallasi,et al.  Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations , 2020, Clinical Cancer Research.

[11]  Z. Szallasi,et al.  Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents , 2019, Genome Biology.

[12]  E. Antonarakis,et al.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.

[13]  A. Chinnaiyan,et al.  Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer , 2019, Clinical Cancer Research.

[14]  W. Isaacs,et al.  Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. , 2019, JCO precision oncology.

[15]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[16]  E. Antonarakis,et al.  Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. , 2019, Journal of Clinical Oncology.

[17]  J. Gregg,et al.  Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors , 2019, JCO precision oncology.

[18]  R. Nussbaum,et al.  Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines , 2019, JAMA oncology.

[19]  H. Scher,et al.  Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. , 2019, Journal of Clinical Oncology.

[20]  J. Reid,et al.  Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer , 2018, British Journal of Cancer.

[21]  Rui Bi,et al.  The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. , 2018, Journal of the National Cancer Institute.

[22]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[23]  Robert Brown,et al.  Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy , 2018, Molecular Cancer Research.

[24]  G. Cancel-Tassin,et al.  Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy , 2018, World Journal of Urology.

[25]  Bruce Montgomery,et al.  Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[27]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[28]  J. Eshleman,et al.  MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.

[29]  K. Cooney,et al.  Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death , 2017 .

[30]  E. Kohn,et al.  Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization , 2017, Clinical Cancer Research.

[31]  F. d’Adda di Fagagna,et al.  A novel single‐cell method provides direct evidence of persistent DNA damage in senescent cells and aged mammalian tissues , 2017, Aging cell.

[32]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[33]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[34]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[35]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[36]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[37]  J. Hicks,et al.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas , 2015, The Prostate.

[38]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[39]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[40]  F. Couch,et al.  Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.

[41]  Benjamin J. Raphael,et al.  Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.

[42]  J. Hicks,et al.  Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.

[43]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[44]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[45]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[47]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.